By the time-kill curve method, the combination of N-formimidoyl thienamycin and gentamicin showed synergism against 47 of 48 strains of enterococci, whereas the combination of N-formimidoyl thienamycin and tobramycin was synergistic against 46 strains. N-Formimidoyl' thienamycin (MK0787) is a stable derivative of thienamycin, a novel Plactam not containing a sulfur atom in the secondary ring, derived from Streptomyces cattleya. N-Formimidoyl thienamycin has been shown to have a wide antimicrobial spectrum, including gram-positive cocci and gram-negative bacilli (2, 3, 5) . In contrast to the third-generation cephalosporins and other new 1-lactams, Nformimidoyl thienamycin has been reported to be active against enterococci (2, 3). In this investigation, we studied the in vitro activity of N-formimidoyl thienamycin against enterococci and the effects of combining N-formimidoyl thienamycin with gentamicin or with tobramycin against enterococci by the time-kill curve method.
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Forty-eight strains of enterococci were used in this study. All and the MBC ranged from 16 to >64 ,ug/ml (median, 32 ,ug/ml).
The combination of N-formimidoyl thienamycin and gentamicin demonstrated synergism at 6, 24, and 48 h (Fig. 1) against 47 of 48 strains of enterococci, and the combination of N-formimidoyl thienamycin and tobramycin was synergistic against 45 of 48 strains (Table 1) . N-Formimidoyl thienamycin-gentamicin and Nformimidoyl thienamycin-tobramycin showed no synergism against a strain of Streptococcus faecalis. N-Formimidoyl thienamycin-tobramy- The results of this study confirm the in vitro activity of N-formimidoyl thienamycin against enterococci (2, 3). As with penicillin and vancomycin, N-formimidoyl thienamycin is not bactericidal against enterococci. Also similar to penicillin and vancomycin (6, 7) , synergism of Nformimidoyl thienamycin with gentamicin and N-formimidoyl thienamycin with tobramycin was demonstrated against almost all strains tested. Both combinations failed to show synergism against one strain of Streptococcusfaecalis. The combination of N-formimidoyl thienamycin and tobramycin showed no synergism against the only strain of Streptococcus faecium. It has been reported that the combination of penicillin and tobramycin is also not synergistic against Streptococcus faecium (4) .
The combination of N-formimidoyl thienamycin and gentamicin or N-formimidoyl thienamycin and tobramycin shows promise as a useful therapeutic regimen in enterococcal endocarditis when penicillin cannot be used. Therapeutic trials in animal models are warranted.
